Riskpilot← Back to searchSign inGet full accessPHARMA NORD ApS
APSActiveCVR 67303016Tinglykke 4-6Manufacture of other food products n.e.c. · NACE 1089Est. 1981300 employees
Revenue 2024
DKK 486,7M
+9% vs 2023
EBITDA margin
9.6%
+65% vs 2023
Equity ratio
35.4%
Financial strength
Net profit 2024
DKK 32,3M
+38% vs 2023
| Revenue | DKK 486,7M | +9% |
| EBITDA | DKK 46,7M | +65% |
| Net profit | DKK 32,3M | +38% |
| Total assets | DKK 405,3M | -5% |
| Equity | DKK 143,3M | -11% |
| Employees | 300 | — |
Legal name
PHARMA NORD ApS
CVR number
67303016
Legal form
Anpartsselskab
NACE code
1089 · Manufacture of other food products n.e.c.
Founded
2. oktober 1981
Share capital
DKK 200.000
Employees
300 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af den samlede bestyrelse, af den samlede direktion eller af den administrerende direktør.
Company purpose
Selskabets formål er handel - herunder eksport, import - produktion samt anden i forbindelse hermed stående virksomhed, bl.a. restaurationsvirksomhed
Address
Tinglykke 4-6
Phone
+4574541155
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 317.354 | 317.138 | — | 337.277 | 343.074 | 333.989 | 332.992 | 417.178 | 470.180 | 439.437 | 447.388 | 486.691 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -70.337 | -74.241 | -0 | -76.769 | -83.992 | -89.143 | -92.395 | -139.113 | -152.032 | -138.012 | -119.241 | -133.578 |
| EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 28.384 | 47.265 | 54.931 | 72.633 | 51.415 | 43.155 | 33.744 | 58.770 | 68.941 | 49.523 | 28.340 | 46.720 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -8.772 | -10.578 | -0 | -8.421 | -11.139 | -9.698 | -8.691 | -9.143 | -9.852 | -10.875 | -10.734 | -11.427 |
| EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 19.612 | 36.687 | 54.931 | 64.212 | 40.276 | 33.457 | 25.053 | 49.627 | 59.089 | 38.648 | 17.606 | 35.293 |
| Net financials | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -7.388 | -1.321 | 0 | 10.535 | 14.704 | 11.127 | 22.117 | 12.782 | 11.956 | 4.428 | 8.417 | 4.011 |
| Profit before tax | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 12.224 | 35.366 | 54.931 | 74.747 | 54.980 | 44.584 | 47.170 | 62.409 | 71.045 | 43.076 | 26.023 | 39.304 |
| Tax | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | 1.073 | 5.127 | -0 | 12.735 | 8.190 | 6.872 | 5.669 | 10.460 | 13.079 | 7.787 | 2.686 | 7.050 |
| Net profit | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 11.151 | 30.238 | 54.931 | 62.012 | 46.790 | 37.712 | 41.501 | 51.949 | 57.966 | 35.289 | 23.337 | 32.254 |
| Item | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 342.144 | 327.520 | 141.720 | 319.064 | 336.241 | 356.840 | 392.558 | 415.020 | 460.569 | 447.011 | 427.094 | 405.332 |
| Equity | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -215 | 29.760 | 200 | 141.996 | 181.881 | 212.710 | 269.730 | 170.425 | 199.348 | 183.029 | 160.565 | 143.344 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 206.561 | 165.399 | 0 | 52.913 | 46.024 | 42.572 | 40.329 | 40.273 | 53.734 | 51.067 | 48.409 | 45.723 |
| Short-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 135.798 | 132.361 | 0 | 116.767 | 99.565 | 91.105 | 70.291 | 190.749 | 193.481 | 195.687 | 200.416 | 198.067 |
| Total debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 342.360 | 297.760 | 0 | 169.680 | 145.589 | 133.677 | 110.620 | 231.022 | 247.215 | 246.754 | 248.825 | 243.790 |
EBITDA margin
9.6%
This company
15.8%
Market median
-39% vs market
19992024
Equity ratio
35.4%
This company
38.2%
Market median
+7% vs market
19992024
Return on equity
22.5%
This company
18.4%
Market median
+22% vs market
19992024
Net profit margin
6.6%
This company
8.1%
Market median
-19% vs market
19992024
Asset turnover
1.20×
This company
1.12×
Market median
+7% vs market
19992024
Debt / equity
1.83×
This company
0.62×
Market median
-195% vs market
19992024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via CVR / Virk · Period 2011-01-01 – 2011-12-31
- Annual report 2010Filed via CVR / Virk · Period 2010-01-01 – 2010-12-31
- Annual report 2009Filed via CVR / Virk · Period 2009-01-01 – 2009-12-31
- Annual report 2008Filed via CVR / Virk · Period 2008-01-01 – 2008-12-31
- Annual report 2007Filed via CVR / Virk · Period 2007-01-01 – 2007-12-31
- Annual report 2006Filed via CVR / Virk · Period 2006-01-01 – 2006-12-31
- Annual report 2005Filed via CVR / Virk · Period 2005-01-01 – 2005-12-31
- Annual report 2004Filed via CVR / Virk · Period 2004-01-01 – 2004-12-31
- Annual report 2003Filed via CVR / Virk · Period 2003-01-01 – 2003-12-31
- Annual report 2002Filed via CVR / Virk · Period 2002-01-01 – 2002-12-31
- Annual report 2001Filed via CVR / Virk · Period 2001-01-01 – 2001-12-31
- Annual report 2000Filed via CVR / Virk · Period 2000-01-01 – 2000-12-31
- Annual report 1999Filed via CVR / Virk · Period 1999-01-01 – 1999-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
Mr Audit | Audit | 1981 | — | — |
EW Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2009 | — | — | |
| Chairman | 2009 | — | — | |
| Board of Directors | 2009 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
PHARMCO I ApS | Company | 50.0% | 50.0% | 2018 |
PharmCo III ApS | Company | 33.3% | 33.3% | 2020 |
| Individual | 33.3% | 33.3% | 2018 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
PHARMCO I ApS
PHARMA NORD ApS Board members of PHARMA NORD ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| MVN revision | Audit | 0 companies |
| Eli Wallin | Chief Executive Officer | 0 companies |
| Claus Hancke | Board of Directors | 0 companies |
| Michael Christiani Havemann | Chairman | 0 companies |
| Bent Henriksen | Board of Directors | 0 companies |